Phage depolymerases Dep46, klebsiella pneumoniae phagocytic strain JSP3 and application

By expressing and purifying the phage depolymerase Dep46 of Klebsiella pneumoniae phage strain JSP3, the problem of poor degradation performance of Klebsiella pneumoniae capsular polysaccharides and biofilm in the prior art was solved, and the problem of poor degradation of Klebsiella pneumoniae KL107 pneumoniae was achieved. The effective degradation and biofilm inhibition of Klebsiella KL107 pneumoniae has significant clinical application value.

CN119082086APending Publication Date: 2024-12-06JIANGSU UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411284587.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing phage depolymerases have poor degradation performance on different types of Klebsiella pneumoniae capsular polysaccharides and biofilm, especially for Klebsiella pneumoniae KL107, making it difficult to effectively control its infection.

Method used

Develop a phage depolymerase Dep46, which can efficiently degrade KL107 pneumoniae by expressing the 46th open reading frame (orf46) gene of Klebsiella pneumoniae phage strain JSP3, prokaryotic expression and purification. Capsular polysaccharides and inhibit the formation of biofilm.

Benefits of technology

Dep46 can significantly remove the capsular polysaccharide formed by Klebsiella pneumoniae KL107 and has an efficient inhibitory effect on the formation of biofilm. It is widely used in antibiotic replacement preparations and medical device disinfectants, which significantly improves the clinical practice. Treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082086A_ABST
    Figure CN119082086A_ABST
Patent Text Reader

Abstract

The invention discloses a bacteriophage depolymerizing enzyme Dep46, a klebsiella pneumoniae phage strain JSP3 and application of the bacteriophage depolymerizing enzyme Dep46 and the klebsiella pneumoniae phage strain The phage depolymerizing enzyme Dep46 is a product obtained by prokaryotic expression and purification of an open reading frame at the 46th site of a phage strain JSP3, the phage strain JSP3 is preserved in the China Center for Type Culture Collection on May 30, 2024, the preservation name is Klebsiella pneumoniae phage JSP3, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: M 20241101. The bacteriophage depolymerases Dep46 can remove capsular polysaccharide formed by KL107 type klebsiella pneumoniae, has an efficient inhibition effect on formation of a biofilm, can be widely applied to preparation of antibiotic substitute preparations and medical instrument disinfectants, and has a remarkable clinical effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a bacteriophage depolymerase Dep46, a Klebsiella pneumoniae phage strain JSP3 and applications thereof. Background Art

[0002] Klebsiella pneumoniae is a common zoonotic pathogen that can cause a wide range of hospital-acquired or community-acquired diseases, such as pneumonia, urinary tract infections, respiratory tract infections, surgical wound infections, suppurative liver abscesses, and bloodstream infections. At the same time, Klebsiella pneumoniae can cause mastitis in cattle and pigs, enteritis in dogs, and sporadic sepsis in many species. Klebsiella pneumoniae poses a huge threat to human public health and animal husbandry. Due to the irrational use of antibiotics, the drug resistance of Klebsiella pneumoniae is becoming more and more serious, making it increasingly difficult to cure Klebsiella pneumoniae infections clinically. In recent years, the number of infections with carbapenem-resistant Klebsiella pneumoniae (CRKP) has increased dramatically, posing a huge challenge to clinical treatment. Innovative treatment options for bacterial infections or improved antibiotic substitute strategies are very important.

[0003] Klebsiella pneumoniae is usually wrapped in a thick layer of capsular polysaccharide (CPS), which helps to evade the host defense system. Capsular polysaccharide is an important virulence factor of bacteria, which helps bacteria escape the detection of the host immune system during infection and protects bacteria from phagocytosis and serum killing. In addition, some Klebsiella pneumoniae can form biofilms, which are membrane-like structures formed by bacteria wrapped in extracellular polysaccharide matrix, lipoprotein, fibrin, etc. produced by the bacteria themselves. This biofilm can not only serve as a physical barrier to wrap bacteria, resist the attack of bacteriophages or other harmful substances, but also reduce the penetration of antibiotics and resist the host's immune system to a certain extent, playing an important role in bacterial infection. Clinically, the formation of Klebsiella pneumoniae biofilm is seen on the inner surface of catheters and physical therapy equipment. It is difficult to remove by conventional physical and chemical means, which may cause colonization and worsening of invasive infection, bringing severe challenges to the prevention and control of medical secondary infections. Therefore, it is very important to develop alternative strategies to control biofilm-related infections.

[0004] Bacteriophages are viruses that naturally lyse bacteria and exhibit high antibacterial effects in vitro. Bacteriophages provide a natural, highly specific and non-toxic way to prevent and control bacterial biofilms. Compared with antibiotics, phage therapy is highly specific and effective against target bacteria, does not cause side effects in the body, and remains stable until the bacteria are cleared.

[0005] Phage-derived depolymerases can specifically bind to and degrade bacterial capsular polysaccharides, thereby guiding the phage to adsorb to the host bacterial outer membrane protein. Phage-derived depolymerases are usually located at the tip of the phage tail or substrate, and can target the degradation of bacterial capsular polysaccharides, destroy the host bacterial capsular barrier, and increase its sensitivity to antibiotics and immune attacks. Depolymerases have unique advantages such as high stability, strong specificity, and high efficiency in inhibiting biofilm formation, and have great potential for antibacterial applications. Current studies have shown that phage depolymerases can effectively inhibit the formation of bacterial biofilms and remove the formed biofilm structures, and have broad application prospects and potential in public health fields such as controlling pathogenic infections. However, phage depolymerases from different sources, different nucleic acid sequences, and different protein structures also have very different degradation performances on different types of capsular polysaccharides and biofilms. For example, the document "Biological properties and genetics analysis of vB_KpnS_GH-K3, a Klebsiella phage with a putative depolymerase-like protein, Virus Genes (2019) 55: 696–706" discloses a bacteriophage depolymerase-like protein, which is shown to only work on K2 type and has no degradation effect on the capsular polysaccharide and biofilm of Klebsiella pneumoniae of KL107 type. The patent with application number CN201811349779.2 and name "Bacteriophage depolymerase for degrading Klebsiella pneumoniae capsular polysaccharide and biofilm" discloses a bacteriophage depolymerase and its application, but does not disclose the actual action spectrum of the bacteriophage depolymerase. Summary of the invention

[0006] In order to overcome the shortcomings and deficiencies of the prior art, the primary purpose of the present invention is to provide a bacteriophage depolymerase Dep46.

[0007] Another object of the present invention is to provide the application of the above-mentioned bacteriophage depolymerase Dep46.

[0008] Another object of the present invention is to provide a Klebsiella pneumoniae phage strain JSP3 expressing the above-mentioned phage depolymerase Dep46.

[0009] Another object of the present invention is to provide a method for preparing phage depolymerase Dep46 from the above-mentioned Klebsiella pneumoniae phage strain JSP3.

[0010] The present invention is achieved by providing a bacteriophage depolymerase Dep46, the amino acid sequence of which is shown in SEQ ID No: 1.

[0011] Preferably, the nucleotide sequence encoding the bacteriophage depolymerase Dep46 is shown in SEQ ID No:2.

[0012] The present invention further discloses the use of the bacteriophage depolymerase Dep46 in the preparation of Klebsiella pneumoniae capsular polysaccharide and biofilm degradation drugs.

[0013] Preferably, the Klebsiella pneumoniae is KL107 type Klebsiella pneumoniae.

[0014] The present invention further discloses the application of the bacteriophage depolymerase Dep46 in the preparation of antibiotic substitute preparations and medical device disinfectants.

[0015] The present invention further discloses a Klebsiella pneumoniae phage strain JSP3 expressing the above-mentioned phage depolymerase Dep46. The phage strain JSP3 was deposited in the China Center for Type Culture Collection on May 30, 2024, with a preservation address of Wuhan University Collection Center, Luojia, Wuchang District, Wuhan City, Postal Code: 430072, with a preservation name of Klebsiella pneumoniae phageJSP3 and a preservation number of CCTCC NO: M20241101.

[0016] Preferably, the bacteriophage depolymerase Dep46 is the prokaryotic expression and purification product of the 46th open reading frame of the Klebsiella pneumoniae phage strain JSP3.

[0017] The present invention further discloses a method for preparing the above-mentioned bacteriophage depolymerase Dep46, which comprises the following steps:

[0018] (1) connecting the Dep46 gene fragment of the 46th open reading frame of the Klebsiella pneumoniae phage strain JSP3 to the pET28a plasmid to obtain the pET28a-Dep46 plasmid; wherein the phage strain JSP3 was deposited in the China Center for Type Culture Collection on May 30, 2024, with the deposit address: Wuhan University Collection Center, Luojia, Wuchang District, Wuhan City, Postal Code: 430072, with the deposit name Klebsiella pneumoniae phage JSP3, and the deposit number: CCTCC NO: M 20241101;

[0019] (2) The pET28a-Dep46 plasmid was transformed into Escherichia coli BL21, and BL21-Dep46 Escherichia coli was screened and cultured in 1 L LB liquid medium containing 50 μg / mL kanamycin at 37° C. with shaking until the logarithmic growth phase;

[0020] (3) adding isopropyl-β-D-thiogalactoside to the above LB liquid medium to a final concentration of 0.3 mM, and inducing expression at 18°C ​​and 180 rpm;

[0021] (4) The induced BL21-Dep46 bacterial solution was centrifuged and then ultrasonically disrupted. The supernatant sample was added to a Ni-NTA affinity chromatography column, the Ni column was washed to remove impurities, and the eluate was collected and ultrafiltered to obtain the purified bacteriophage depolymerase Dep46.

[0022] Compared with the shortcomings and deficiencies of the prior art, the present invention has the following beneficial effects: the present invention obtains the phage depolymerase Dep46 by prokaryotic expression and purification of the 46th open reading frame (orf46) of the Klebsiella pneumoniae phage strain JSP3, and the depolymerase can remove the capsular polysaccharide formed by KL107 type Klebsiella pneumoniae, and has a high efficiency inhibitory effect on the formation of biofilm, can be widely used in the preparation of antibiotic substitute preparations and medical device disinfectants, and has a significant clinical effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The phage plaque image and transmission electron microscope image of the phage strain JSP3 of the present invention; wherein, Figure A is the phage plaque image, and Figure B is the transmission electron microscope image;

[0024] Figure 2 It is an agarose gel electrophoresis diagram of the PCR product of the prokaryotic expression strain positive for the bacteriophage depolymerase Dep46 of the present invention;

[0025] Figure 3 The SDS-PAGE electrophoresis diagram of the bacteriophage depolymerase Dep46 before and after purification of the present invention;

[0026] Figure 4 This is a diagram showing the inhibitory effect of different concentrations of the depolymerase Dep46 on KL107 type Klebsiella pneumoniae Kp42 in the examples of the present invention;

[0027] Figure 5 The results of the detection of the depolymerase Dep46 depolymerizing the Klebsiella pneumoniae capsule in the embodiment of the present invention; Figure A is a transmission electron micrograph of Kp2 after treatment with the depolymerase Dep46, and Figure B is a transmission electron micrograph of Kp2 after treatment with PBS buffer in the control group;

[0028] Figure 6 This is the detection result of Dep46 inhibiting Klebsiella pneumoniae biofilm in the example of the present invention. DETAILED DESCRIPTION

[0029] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0030] Example 1 Preparation of bacteriophage depolymerase Dep46

[0031] 1. Inoculation and cultivation of phage strain JSP3

[0032] Collect sewage and place it in a 4℃ refrigerator for more than 4 hours. Collect the upper liquid and place it in a new sterile 50mL centrifuge tube. Centrifuge at 4,000×g for 10 minutes. Take the supernatant and filter it with a 0.22μm filter. Mix the filtrate with Klebsiella pneumoniae Kp2 (host bacteria, isolated from clinical blood flow patients) in a ratio of 1:1, add the mixture to the melted 55℃ LB semi-solid culture medium and mix it thoroughly, pour it into the LB solid plate, culture at 37℃ for 6-12 hours, pick the plaques and mix them in 1mL SM solution, dilute them in multiples and culture them using the double-layer plate method. Repeat the above operation 3 times. Figure 1 As shown in A, the phage isolate JSP3 was obtained. After the phage strain JSP3 was mixed with Klebsiella pneumoniae Kp2, double-layer plates were spread and cultured for 6 to 12 hours. 4 mL of SM buffer was added to each plate and placed on a shaker at 4°C and 50 rpm for 2 hours. The liquid was aspirated from the double-layer plate into a sterile EP tube, centrifuged at 4,000 × g for 5 minutes, and the supernatant was filtered and sterilized with a 0.22 μm filter. 20 μL of the filtrate of the proliferated and purified phage strain was aspirated and dropped onto a copper mesh, dried under an incandescent lamp, and then negatively stained with phosphotungstic acid (PTA, 2% w / v). Using an HT_7800 transmission electron microscope, the phage morphology was observed and electron micrographs were taken, as shown in the figure. Figure 1 As shown in B.

[0033] 2. Amplification of target product

[0034] (1) Design of primers for constructing a depolymerase expression vector:

[0035] Upstream primer F (SEQ ID No: 3) is:

[0036] 5'-GTGCCGCGCGGCAGCCATATGACTAACGTGGCATTCAGTTGG-3';

[0037] Downstream primer R (SEQ ID No: 4) is:

[0038] 5'-GTGCCGCGCGGCAGCCATATGACTAACGTGGCATTCAGTTGG-3'.

[0039] The PCR amplification program was denaturation at 95°C for 3 min, denaturation at 95°C for 15 s, annealing at 52°C for 15 s, and extension at 72°C for 2 min, for 30 cycles.

[0040] The Dep46 gene PCR product from the 46th open reading frame of Klebsiella pneumoniae phage strain JSP3 was purified and ligated into the pET28a plasmid (with restriction sites Nde I and Xho I) to obtain the pET28a-Dep46 recombinant plasmid;

[0041] (2) Add the pET28a-Dep46 recombinant plasmid to 100 μL of E. coli BL21 (DE3) competent cells, gently tap the tube wall to mix, and let it stand on ice for 30 minutes. After heat shock in a 42°C water bath for 90 seconds, quickly place it on ice for 2 minutes. Add 900 μL of SOC liquid culture medium to the centrifuge tube, mix well, and place it in a shaker at 37°C, 180 rpm for 1 hour. Centrifuge at 2500×g for 3 minutes, discard 900 μL of supernatant, resuspend the bacteria with the remaining culture medium, and evenly spread it on an LB solid culture medium plate containing kanamycin. Place the plate upright in a 37°C incubator for 10 minutes. After the bacterial solution is completely absorbed, invert the plate and culture overnight. Amplify using the universal T7 primer, and then screen by agarose gel electrophoresis to obtain BL21-Dep46 positive clone E. coli; the agarose gel electrophoresis image is shown as follows Figure 2 As shown, lane M is a marker, and lanes 1, 2, 3, 4 and 5 are PCR products of randomly selected single colonies.

[0042] (3) BL21-Dep46 was cultured in 1 L LB liquid medium containing 50 μg / mL kanamycin at 37°C with shaking until the logarithmic growth phase (OD 600 0.6~1.0);

[0043] (4) adding isopropyl-β-D-thiogalactoside to the culture medium to a final concentration of 0.3 mM and incubating at 18°C ​​and 180 rpm with shaking for 16 h;

[0044] (5) The induced BL21-Dep46 bacterial solution was centrifuged (5000rpm, 10min), and the bacteria were washed 2-3 times with pre-cooled PBS buffer, and then suspended with an appropriate amount of protein purification dissolution buffer. The suspended BL21-Dep46 bacterial solution was placed in an ice bath, and then ultrasonically disrupted (working for 3sec, resting for 6sec, and ice bathing throughout the process), centrifuged, and the supernatant was aspirated. The supernatant sample was gently added to the balanced Ni-NTA affinity chromatography column. After the supernatant was fully combined with the Ni column, the Ni column was washed with 4 column volumes of washing buffer containing 50mM imidazole and 100mM imidazole to remove impurities. Then, the target protein was eluted with 4 column volumes of eluent containing 250mM imidazole. After collecting the eluent, the purified phage depolymerase Dep46 was obtained by ultrafiltration, and its amino acid sequence is shown in SEQ ID No: 1, and the nucleotide sequence is shown in SEQ ID No: 2. The concentration of purified bacteriophage depolymerase Dep46 was measured using a BCA protein quantification kit, and the product was aliquoted and stored in a -80°C refrigerator.

[0045] 3. SDS-PAGE electrophoresis analysis

[0046] Prepare 10% separation gel and 5% concentration gel as shown in Table 1 and Table 2 below:

[0047] Table 1 SDS-PAGE separation gel (10% acrylamide)

[0048] Solution components Volume (mL) <![CDATA[ddH2O]]> 4 30% Acrylamide 3.3 1.5 mol / L Tris·HCl (pH 8.8) 2.5 10% SDS 0.1 10% ammonium persulfate (AP) 0.1 TEMED 0.004 Total 10

[0049] Table 2 SDS-PAGE stacking gel (5% acrylamide)

[0050] Solution components Volume (mL) <![CDATA[ddH2O]]> 6.8 30% Acrylamide 1.7 1.5 mol / L Tris·HCl (pH 8.8) 1.25 10% SDS 0.1 10% ammonium persulfate (AP) 0.1 TEMED 0.01 Total 10

[0051] The purified sample was boiled for 10 minutes and then loaded. The concentration gel voltage was 80V for 20 minutes, the separation gel voltage was 120V, and the electrophoresis was performed for 1.5 hours. Coomassie brilliant blue staining was performed and the decolorization observation showed that a clear band appeared at ~130kDa. The electrophoresis of the purified protein is shown in the figure below. Figure 3 As shown, lane 1 is the marker, lane 2 is the supernatant protein before passing through the nickel column, and lane 3 is the purified protein.

[0052] Example 2: Removal of KL107-type bacterial capsular polysaccharide using bacteriophage depolymerase Dep46

[0053] The spot test was used to detect the inhibitory activity of bacteriophage depolymerase Dep46 on Escherichia coli biofilm. 0.5% semi-solid LB medium containing 100 μL of logarithmic phase bacteria was evenly spread on solid LB medium. After natural drying, 5 μL of 4 mg / mL and 0.4 mg / mL Dep46 were respectively spotted on the double-layer plate. Bacteriophage P3 was used as a positive control, and buffer was used as a negative control. The plates were incubated overnight at 37°C. The phage depolymerase Dep46 at concentrations of 4 mg / mL and 0.4 mg / mL formed translucent spots on the plate, as shown in Figure 2. Figure 4 shown.

[0054] Transmission electron microscopy was used to observe the depolymerization activity of the depolymerase Dep46 on the capsule. The bacteria Kp2 cultured on the LB solid plate were collected, then washed and resuspended with PBS buffer. 1000μL of bacterial suspension was treated with 50μg of depolymerase or PBS buffer for 1h. The precipitate after centrifugation was fixed with 5% glutaraldehyde at room temperature for 2h, and then fixed with 2% osmium tetroxide. The bacteria were dehydrated and embedded in epoxy resin. After sectioning, they were stained with uranyl acetate and lead citrate, and finally detected with a Hitachi HT_7800TEM system. Capsule transmission electron microscopy showed that the morphological characteristics of the depolymerase Dep46-treated group and the PBS buffer control group were significantly different. The surface of the Kp2 bacteria treated with Dep46 was smooth, indicating that the bacterial capsule was degraded and fell off. However, the surface of the Kp2 bacteria treated with PBS buffer was rough, indicating that the bacterial capsule did not fall off, such as Figure 5 shown.

[0055] Example 3 Inhibition of Klebsiella pneumoniae biofilm KL107 using purified depolymerase Dep46

[0056] 90 μL KL107 Klebsiella pneumoniae Kp2 (OD 600 0.4,~2×10 8CFU / mL) was inoculated into a 96-well cell culture plate containing 100 μL LB medium in each well. The purified Dep46 was diluted with protein buffer, and 10 μL of Dep46 dilution was added to each well of the above wells, with the contents of each well being 40 μg, 4 μg, 0.4 μg, 0.04 μg and 4 ng, respectively. After 48 hours of culture, the cell culture plate was taken out, the culture medium was discarded with a pipette, and the plate was washed twice with sterilized PBS buffer to remove free bacteria and enzymes. Then 200 μL of methanol was added to each well and fixed for 10 minutes. After discarding the fixative and allowing it to dry naturally, it was stained with 200 μL of 0.1% crystal violet at room temperature for 10 minutes. The staining solution was discarded and washed twice with PBS buffer to remove the free staining solution. The cell culture plate was placed in a 50°C oven for drying, and after taking it out, 200 μL of 33% acetic acid solution was added to each well and left for 30 minutes to release the crystal violet in the biofilm. Finally, the absorbance at 595 nm was measured using an enzyme-labeled instrument. 595 The value determines the amount of biofilm residue.

[0057] Figure 6 As shown, the inhibition rates of 40 μg, 4 μg, 0.4 μg, 0.04 μg and 4 ng of the depolymerase Dep46 on the biofilm formed by Klebsiella pneumoniae Kp57 were 76.80%, 64.26%, 59.54%, 32.61%, and 21.68%, respectively.

[0058] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A bacteriophage depolymerase Dep46, It is characterized in that The amino acid sequence of the bacteriophage depolymerase Dep46 is shown in SEQ ID No:

1.

2. The bacteriophage depolymerase Dep46 according to claim 1, It is characterized in that The nucleotide sequence encoding the bacteriophage depolymerase Dep46 is shown in SEQ ID No:

2.

3. Use of the bacteriophage depolymerase Dep46 according to claim 1 or 2 in the preparation of a drug for degrading capsular polysaccharides and biofilms of Klebsiella pneumoniae.

4. The use according to claim 3, It is characterized in that The Klebsiella pneumoniae is KL107 type Klebsiella pneumoniae.

5. Use of the bacteriophage depolymerase Dep46 according to claim 1 or 2 in the preparation of antibiotic substitute preparations and medical device disinfectants.

6. A Klebsiella pneumoniae phage strain JSP3 expressing the phage depolymerase Dep46 according to claim 1 or 2, It is characterized in that The phage strain JSP3 was deposited in the China Center for Type Culture Collection on May 30, 2024, with the collection name Klebsiella pneumoniae phage JSP3 and the collection number: CCTCC NO: M 20241101.

7. The Klebsiella pneumoniae phage strain JSP3 according to claim 6, It is characterized in that The bacteriophage depolymerase Dep46 is a prokaryotic expression and purification product of the 46th open reading frame of the Klebsiella pneumoniae phage strain JSP3.

8. A method for preparing the bacteriophage depolymerase Dep46 according to claim 1 or 2, It is characterized in that The method comprises the following steps: (1) connecting the Dep46 gene fragment of the 46th open reading frame of the Klebsiella pneumoniae phage strain JSP3 to the pET28a plasmid to obtain the pET28a-Dep46 plasmid; wherein the phage strain JSP3 was deposited in the China Center for Type Culture Collection on May 30, 2024, with the deposit name Klebsiella pneumoniae phage JSP3 and the deposit number: CCTCC NO: M20241101; (2) The pET28a-Dep46 plasmid was transformed into Escherichia coli BL21, and BL21-Dep46 Escherichia coli was screened and cultured in 1 L LB liquid medium containing 50 μg / mL kanamycin at 37° C. with shaking until the logarithmic growth phase; (3) adding isopropyl-β-D-thiogalactoside to the above LB liquid medium to a final concentration of 0.3 mM, and inducing expression at 18°C ​​and 180 rpm; (4) The induced BL21-Dep46 bacterial solution was centrifuged and then ultrasonically disrupted. The supernatant sample was added to a Ni-NTA affinity chromatography column, the Ni column was washed to remove impurities, and the eluate was collected and ultrafiltered to obtain the purified bacteriophage depolymerase Dep46.

Citation Information

Patent Citations

  • Bacteriophage depolymerase capable of degrading Klebsiella pneumoniae capsular polysaccharides and biofilms

    CN109536459A